By Hugo DeWitt, Mitch Scanlan, Tim Ward and Christel Fenge
The biopharmaceutical market has enjoyed a significant expansion over the past few years. Around half of the world bestselling drugs are biologics and they account for around the same proportion of sales of the world's top one hundred drugs. Biopharmaceutical product pipelines are burgeoning not least because of the race to commercialise biosimilar products. These are products, marketed once patents on originator molecules have expired, that can bring the benefits of biologics to patients at significantly reduced costs.